Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy.

Abstract

BACKGROUND:

Tumor markers are useful for diagnosis and follow-up. We studied the prognostic value of baseline and serial carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA19.9) measurements in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

METHODS:

Sixty-three patients with pseudomyxoma peritonei were treated with cytoreductive surgery and HIPEC. The tumor markers CEA and CA19.9 were collected before therapy and at 3-month intervals during follow-up.

RESULTS:

Preoperative CEA and CA19.9 levels were increased in, respectively, 75% and 58% of the patients. Baseline tumor marker values were related to the extent of tumor. Immediately after HIPEC, both tumor markers decreased markedly (P <.0001). CA19.9 was shown to be a more useful tumor marker than CEA for follow-up. During follow-up, a high absolute CA19.9 level (P =.0005) was predictive for imminent recurrence. Patients who never attained a normal CA19.9 level showed a higher recurrence rate at 1 year (53%; SE, 15%), in comparison to patients who did so (6%; SE 4%). The median lead time of increased CA19.9 to recurrence was 9 months.

CONCLUSIONS:

The measurement of the tumor marker CA19.9 is useful in evaluating therapy in patients with pseudomyxoma peritonei treated with cytoreductive surgery and HIPEC. CA19.9 is a prognostic factor for predicting recurrent disease.

• Authors: S van Ruth, A A M Hart, J M G Bonfrer, V J Verwaal, F A N Zoetmulder
• Journal: Annals of surgical oncology (Ann Surg Oncol) Vol. 9 Issue 10 Pg. 961-7 (Dec 2002) ISSN: 1068-9265 [Print] United States
• PMID: 12464587 (Publication Type: Journal Article)

Chemical References

• CA-19-9 Antigen
• Carcinoembryonic Antigen

Topics

• Analysis of Variance
• CA-19-9 Antigen (metabolism)
• Carcinoembryonic Antigen (metabolism)
• Disease-Free Survival
• Humans
• Netherlands (epidemiology)
• Peritoneal Neoplasms (diagnosis, mortality, therapy)
• Predictive Value of Tests
• Prognosis
• Proportional Hazards Models
• Pseudomyxoma Peritonei (diagnosis, mortality, therapy)
• Recurrence
• Survival Rate